X0306 4 2022-03-04 0 0001582313 Xenon Pharmaceuticals Inc. XENE 0001620084 PIMSTONE SIMON N. 200 - 3650 GILMORE WAY BURNABY A1 V5G 4W8 BRITISH COLUMBIA, CANADA 1 0 0 0 Common Shares 2022-03-04 4 M 0 10288 3.67 A 220474 D Common Shares 2022-03-04 4 F 0 963 31.42 D 219511 D Common Shares 2022-03-04 4 S 0 4532 30.66 D 214979 D Common Shares 2022-03-04 4 S 0 4793 30.56 D 210186 D Common Shares 2022-03-07 4 M 0 20576 3.67 A 230762 D Common Shares 2022-03-07 4 F 0 1990 30.23 D 228772 D Common Shares 2022-03-07 4 S 0 5037 30.60 D 223735 D Common Shares 2022-03-07 4 S 0 4517 30.49 D 219218 D Common Shares 2022-03-07 4 S 0 4516 30.45 D 214702 D Common Shares 2022-03-07 4 S 0 4516 30.44 D 210186 D Common Shares 2022-03-07 4 S 0 2500 30.52 D 207686 D Common Shares 2022-03-07 4 S 0 7500 30.50 D 200186 D Common Shares 2022-03-07 4 S 0 2500 30.55 D 197686 D Common Shares 2022-03-08 4 S 0 2051 30.60 D 195635 D Common Shares 2022-03-08 4 S 0 2500 3.80 D 193135 D Common Shares 2022-03-08 4 S 0 2500 30.10 D 190635 D Common Shares 2022-03-08 4 S 0 2500 30.20 D 188135 D Common Shares 2022-03-08 4 S 0 2500 30.55 D 185635 D Common Shares 2022-03-08 4 S 0 2500 30.50 D 183135 D Stock Option (Right to Buy) 3.67 2022-03-04 4 M 0 10288 0.00 D 2022-03-10 Common Shares 10288 0 D Stock Option (Right to Buy) 3.67 2022-03-07 4 M 0 20576 0.00 D 2022-03-10 Common Shares 20576 0 D The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.49 to $30.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.53 to $30.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Represents the closing price of the Company's common shares on March 4, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.4865 to $30.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.480 to $30.645, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.4100 to $30.4750, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.40 to $30.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.800 to $30.880, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.55 to $30.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2012 Vesting Commencement Date. Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. /s/ Cassandra Robinson, Attorney-in-fact 2022-03-08